These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 12669372)

  • 1. Overcoming multidrug resistance in gram-negative bacteria.
    Poole K
    Curr Opin Investig Drugs; 2003 Feb; 4(2):128-39. PubMed ID: 12669372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is in the pipeline for Gram-negative pathogens?
    Talbot GH
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):39-49. PubMed ID: 18251663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Will new antimicrobials overcome resistance among Gram-negatives?
    Bassetti M; Ginocchio F; Mikulska M; Taramasso L; Giacobbe DR
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):909-22. PubMed ID: 21973303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options.
    Vergidis PI; Falagas ME
    Curr Opin Investig Drugs; 2008 Feb; 9(2):176-83. PubMed ID: 18246520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial resistance among and therapeutic options against gram-negative pathogens.
    Rahal JJ
    Clin Infect Dis; 2009 Aug; 49 Suppl 1():S4-S10. PubMed ID: 19619021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predominance of Gram-negative bacilli and increasing antimicrobial resistance in nosocomial bloodstream infections at a university hospital in southern Taiwan, 1996-2003.
    Wu CJ; Lee HC; Lee NY; Shih HI; Ko NY; Wang LR; Ko WC
    J Microbiol Immunol Infect; 2006 Apr; 39(2):135-43. PubMed ID: 16604246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The current state of multidrug-resistant gram-negative bacilli in North America.
    Nicasio AM; Kuti JL; Nicolau DP
    Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical applications and feasibility of efflux pump inhibitors in the clinic--a vision for applied use.
    Lomovskaya O; Bostian KA
    Biochem Pharmacol; 2006 Mar; 71(7):910-8. PubMed ID: 16427026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The forgotten Gram-negative bacilli: what genetic determinants are telling us about the spread of antibiotic resistance.
    Gootz TD
    Biochem Pharmacol; 2006 Mar; 71(7):1073-84. PubMed ID: 16359640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug-resistant Gram-negative bacteria in postoperative infections.
    Singh AV; Mishra B; Thakur A
    J Indian Med Assoc; 2009 Mar; 107(3):148-50, 163. PubMed ID: 19810380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospects and challenges of developing new agents for tough Gram-negatives.
    Meyer AL
    Curr Opin Pharmacol; 2005 Oct; 5(5):490-4. PubMed ID: 16084769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance patterns among selective Gram-negative bacilli from an intensive care unit in Trinidad, West Indies.
    Orrett FA
    Saudi Med J; 2004 Apr; 25(4):478-83. PubMed ID: 15083220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-fermentative Gram-negative bacteria.
    Enoch DA; Birkett CI; Ludlam HA
    Int J Antimicrob Agents; 2007 May; 29 Suppl 3():S33-41. PubMed ID: 17659210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of cell wall organization and active efflux pump systems in multidrug resistance of bacteria].
    Hasdemir U
    Mikrobiyol Bul; 2007 Apr; 41(2):309-27. PubMed ID: 17682720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metallo-beta-lactamases in Gram-negative bacteria: introducing the era of pan-resistance?
    Maltezou HC
    Int J Antimicrob Agents; 2009 May; 33(5):405.e1-7. PubMed ID: 19095416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum.
    McGowan JE
    Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S29-37; discussion S64-73. PubMed ID: 16813979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Problems of antibiotic-resistance Gram negative pathogens in the hospital environment].
    Liassine N
    Schweiz Med Wochenschr; 2000 Dec; 130(50):1930-6. PubMed ID: 11189438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and economic burden of antimicrobial resistance.
    Maragakis LL; Perencevich EN; Cosgrove SE
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):751-63. PubMed ID: 18847410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tigecycline: in-vitro performance as a predictor of clinical efficacy.
    Hawkey P; Finch R
    Clin Microbiol Infect; 2007 Apr; 13(4):354-62. PubMed ID: 17359318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The emergence and implications of metallo-beta-lactamases in Gram-negative bacteria.
    Walsh TR
    Clin Microbiol Infect; 2005 Nov; 11 Suppl 6():2-9. PubMed ID: 16209700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.